Recent 8-K filings for CNTB

• September 30, 2026, 7:05 AM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Connect Biopharma's rademikibart cuts COPD treatment failure 81% in Phase 2; plans FDA Phase 3 talks

  Phase 2 Seabreeze STAT (CBP-201-207) enrolled 159 COPD patients with eosinophils >=300 cells/uL; randomized 1:1 to single subcutaneous rademikibart or placebo plus standard of care.

• September 15, 2026, 7:06 AM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Rademikibart Phase 2 asthma: FEV1 up 130mL (p=0.023); treatment failure down 66% (p=0.153)

  FEV1 at Day 7 improved 250 mL vs 120 mL placebo (130 mL delta, p=0.023), a statistically significant key secondary.

• August 12, 2026, 4:13 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Connect Biopharma Q2 net loss $17.3M; enrollment done in both Seabreeze STAT trials

  Q2 2026 net loss $17.3M ($0.27/share) vs $12.9M ($0.23) in Q2 2025; H1 loss $36.7M ($0.61).

• March 31, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Connect Biopharma FY2025 net loss $55.5M; cash runway extended by $20.2M placement

  Net loss FY2025 $55.5M ($1.00 per share) vs $15.6M ($0.28 per share) in FY2024.

• March 30, 2026, 7:59 PM ET other material materiality 0.80 positive item 1.01item 3.02item 7.01item 8.01item 9.01 ◈ Equity Issuances◈ Material Agreements

  Connect Biopharma private placement $20.2M; Phase 1 IV rademikibart shows rapid bronchodilation; Phase 3 AD efficacy

  Raised $20.2M via private placement of 6.13M shares at $3.25; led by Panacea Venture; extends cash runway into H2 2027.

• November 12, 2025, 6:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Connect Biopharma Q3 net loss $17.2M; cash $54.8M; Seabreeze STAT studies on track for 1H26 topline

  Net loss of $17.2M ($0.31 per share) in Q3 2025 vs $12.9M ($0.23) in Q3 2024; 9-month net loss $40.4M ($0.73) vs $6.7M ($0.12).

• August 13, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Connect Biopharma Q2 net loss $12.9M; cash $71.8M; ADR program termination planned

  Net loss $12.9M ($0.23) vs net income $14.8M ($0.27) in Q2 2024; revenue $48K vs $24.1M.

• July 17, 2025, 7:59 PM ET regulatory materiality 0.60 positive item 8.01item 9.01

  Connect Biopharma regains Nasdaq minimum bid price compliance; delisting risk removed

  Received Nasdaq letter on July 17, 2025 confirming compliance with Minimum Bid Price Requirement.

• July 9, 2025, 7:59 PM ET other material materiality 0.70 positive item 7.01item 8.01item 9.01

  Connect licensee Simcere submits NDA for rademikibart in China for atopic dermatitis

  Simcere submitted NDA to NMPA for rademikibart to treat atopic dermatitis in adults and adolescents.

• May 15, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Connect Biopharma Q1 net loss $10.3M; cash $84M; initiates two Phase 2 rademikibart trials

  Cash, equivalents and ST investments $84.0M as of March 31, 2025; runway into 2027.

• May 14, 2025, 7:59 PM ET other material materiality 0.60 neutral item 7.01item 8.01item 9.01

  Connect Biopharma starts Phase 2 COPD study of rademikibart, topline data expected 1H 2026

  Phase 2 Seabreeze STAT COPD study initiated after FDA agreement on final protocol.

• May 13, 2025, 7:59 PM ET other material materiality 0.60 positive item 7.01item 8.01item 9.01

  Connect Biopharma initiates Phase 2 Seabreeze STAT study of rademikibart for acute asthma exacerbations

  Phase 2 Seabreeze STAT Asthma study (NCT06940141) initiated after FDA agreement on final protocol.

• April 1, 2025, 7:59 PM ET regulatory materiality 0.70 positive item 7.01item 8.01item 9.01

  Connect Biopharma gains FDA alignment for Phase 2 trials of rademikibart in acute asthma/COPD

  FDA Type C meeting positive; agency aligned on parallel Phase 2 trials for rademikibart in acute exacerbations of asthma or COPD.

• March 31, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Connect Biopharma reports FY2024 net loss $15.6M; cash $93.7M into 2027

  Revenue $26.0M from Simcere license; no revenue in FY2023.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

9 positive 1 negative 10 neutral

source · CNTB on sec.gov